Process for the synthesis of E1 activating enzyme inhibitors

US10745404B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10745404-B2
Application numberUS-201715713293-A
CountryUS
Kind codeB2
Filing dateSep 22, 2017
Priority dateAug 2, 2007
Publication dateAug 18, 2020
Grant dateAug 18, 2020

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention provides processes and synthetic intermediate (Ia) for the synthesis of 4-substituted ((1S, 2S, 4R)-2-hydroxy-4-{7H-pyrrolo[2,3-d]pyrimidin-7-yl}cyclopentyl)methyl sulfamates. These sulfamate compounds are E1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with E1 activity.

First claim

Opening claim text (preview).

What is claimed is: 1. A compound of formula (Ia): or a salt thereof; wherein: stereochemical configurations depicted at asterisk positions indicate absolute stereochemistry; R a is hydrogen; or R a taken together with R j and the intervening atoms forms a cyclic diol protecting group; R b is hydrogen; R c is hydrogen; R d is hydrogen; R e is hydrogen; R e′ is hydrogen; each R f is independently hydrogen; R g′ is chloro, bromo, fluoro, or iodo; R h is hydrogen; R h′ is hydrogen; R j is hydrogen; or R j taken together with R a and the intervening atoms forms a cyclic diol protecting group; R k is hydrogen. 2. The compound of claim 1 , wherein the compound is: 3. The compound of claim 1 , wherein each of R a and R j is hydrogen. 4. The compound of claim 3 , wherein R g′ is chloro, bromo, or iodo. 5. The compound of claim 4 , wherein R g′ is chloro or bromo. 6. The compound of claim 1 , wherein R g′ is chloro, bromo, fluoro, or iodo. 7. The compound of claim 6 , wherein R g′ is chloro or bromo.

Assignees

Inventors

Classifications

  • Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups · CPC title

  • Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

  • Sulfur atom · CPC title

  • C07D487/04Primary

    Ortho-condensed systems · CPC title

  • at least one of the nitrogen atoms being part of any of the groups [IMAGE cpc-sch-C07C-0976.gif], X being a hetero atom, Y being any atom · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10745404B2 cover?
The present invention provides processes and synthetic intermediate (Ia) for the synthesis of 4-substituted ((1S, 2S, 4R)-2-hydroxy-4-{7H-pyrrolo[2,3-d]pyrimidin-7-yl}cyclopentyl)methyl sulfamates. These sulfamate compounds are E1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with E1 activity.
Who is the assignee on this patent?
Millennium Pharm Inc
What technology area does this patent fall under?
Primary CPC classification C07D487/04. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Aug 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).